Related Experiment Video
Updated: Dec 10, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
Michael Brandon Ware1, Bassel F El-Rayes1, Gregory B Lesinski2
1Hematology and Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is plagued by a dismal 5-year survival rate, early onset of metastasis and limited efficacy of systemic therapies. This scenario highlights the need to fervently pursue novel therapeutic strategies to treat this disease. Recent research has uncovered complicated dynamics within the tumor microenvironment (TME) of PDAC. An abundant stroma provides a framework for interactions between cancer-associated fibroblasts, suppressive myeloid cells and regulatory lymphocytes, which together create an inhospitable environment for adaptive immune responses. This accounts for the poor infiltration and exhausted phenotypes of effector T cells within pancreatic tumors. Innovative studies in genetically engineered mouse models have established that with appropriate pharmacological modulation of suppressive elements in the TME, T cells can be prompted to regress pancreatic tumors. In light of this knowledge, innovative combinatorial strategies involving immunotherapy and targeted therapies working in concert are rapidly emerging. This review will highlight recent advances in the field related to immune suppression in PDAC, emerging preclinical data and rationale for ongoing immunotherapy clinical trials. In particular, we draw attention to foundational findings involving T-cell activity in PDAC and encourage development of novel therapeutics to improve T-cell responses in this challenging disease.
Insights
Pancreatic cancer (PDAC) has poor survival rates due to its tumor microenvironment. Modulating this environment can enhance T-cell activity, offering new hope for effective pancreatic cancer treatments.
Area of Science:
- Oncology
- Immunology
- Cancer Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits a dismal 5-year survival rate, early metastasis, and limited treatment efficacy.
- The tumor microenvironment (TME) in PDAC is characterized by abundant stroma, fostering interactions that suppress adaptive immune responses.
- This immune suppression leads to poor T-cell infiltration and function within pancreatic tumors.
Purpose of the Study:
- To review recent advances in understanding immune suppression in PDAC.
- To highlight emerging preclinical data and the rationale for current immunotherapy clinical trials.
- To encourage the development of novel therapeutics targeting T-cell responses in PDAC.
Main Methods:
- Review of recent scientific literature on PDAC immunology and therapeutics.
- Analysis of preclinical data from genetically engineered mouse models.
- Examination of ongoing clinical trials for PDAC immunotherapy.
Main Results:
- Pharmacological modulation of the PDAC TME can potentially enhance T-cell activity.
- Genetically engineered mouse models demonstrate T-cell-mediated tumor regression upon TME modulation.
- Combinatorial strategies involving immunotherapy and targeted therapies are emerging.
Conclusions:
- Targeting immune suppressive elements within the PDAC TME is a promising therapeutic avenue.
- Enhancing T-cell activity holds potential for improving treatment outcomes in pancreatic cancer.
- Further development of novel therapeutics is crucial for overcoming challenges in PDAC treatment.
Related Concept Videos
01:27Tumor Immunotherapy
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...